KetamineOne Capital announced that its common shares have been successfully uplisted from the OTC Pink Sheet Open Market to the OTCQB Venture Market by the OTC Markets Group Inc. (OTCQX:OTCM)
The company’s common shares will begin trading on the OTCQB under the symbol KONEF as of the opening of the market today, January 12, 2022. The company said the uplisting complements its previous receipt of DTC Eligibility.
“We are pleased for Ketamine One (NEO:MEDI.AQN)’s common shares to be accepted onto the OTCQB by OTC Markets. The listing of our shares on the OTCQB is important as it makes it easier for American investors to obtain information about our securities and purchase our stock. Combined with DTC Eligibility, the Up-Listing enables US residents who are interested in the mental health revolution to become shareholders and participate in our growth,” said Adam Deffett, interim chief executive officer of Ketamine One (NEO:MEDI.AQN) in a statement.
READ: Ketamine One says its subsidiary KGK Science becomes first founding sponsor of Psychedelic Science 2023 event
“Now with our common shares being listed on the NEO Exchange, Frankfurt Stock Exchange and OTCQB, it is easier than ever before for investors in the world’s major capital markets to become owners of Ketamine One’s securities,” he added.
Ketamine One’s common shares will continue to trade on the NEO Exchange under the symbol MEDI and the Frankfurt Stock Exchange under the symbol MY0.
Operated by OTC Markets, the OTCQB offers transparent trading in entrepreneurial and development stage companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process.
The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. These standards provide a strong baseline of transparency, as well as the technology and regulations to improve the trading experience for investors.
KetamineOne Capital is focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry.
KGK Science Inc. is the company’s wholly-owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries.
Contact the author at jon.hopkins@proactiveinvestors.com